BioLineRx Ltd. (BLRX)

NCM – Real Time Price. Currency in USD

2.37

-0.02 (-0.84%)

At close: Mar 27, 2026, 4:00 PM EDT

2.39

+0.02 (0.84%)

After-hours: Mar 27, 2026, 4:10 PM EDT

26.03.2026

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

GLIX1, a TET2 activator , is a first -in- class , oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated potent anti-tumor activity in multiple GBM models, excellent blood-brain barrier penetration and a favorable safety profile in preclinical toxicology studies Study is being conducted by world-leading glioblastoma investigators, led by Dr. Roger Stupp TEL AVIV, Israel, March 26, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive GBM and other high-grade glioma (NCT07464925).

23.03.2026

BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript

23.03.2026

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month - - GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms - - Management to host conference call today, March 23, at 8:30 am EDT - TEL AVIV, Israel, March 23, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2025, and provided a corporate update.

16.03.2026

BioLineRx to Report 2025 Annual Results on March 23, 2026

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, March 16, 2026 /PRNewswire/ -- BioLineRx Ltd.

24.11.2025

BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript

BioLineRx Ltd. ( BLRX ) Q3 2025 Earnings Call November 24, 2025 8:30 AM EST Company Participants Irina Koffler - Managing Director Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Ella Sorani - Chief Development Officer Conference Call Participants Joseph Pantginis - H.C.

24.11.2025

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers - - Phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026 - - Management to host conference call today, November 24 th, at 8:30 am EST - TEL AVIV, Israel , Nov. 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended September 30, 2025, and provided a corporate update.

18.11.2025

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 18, 2025 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Ltd. (BLRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

BioLineRx Ltd. (BLRX)

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

BioLineRx to Report 2025 Annual Results on March 23, 2026

BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

BioLineRx to Report 2025 Annual Results on March 23, 2026

BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Videos

No Data

Press releases

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types